期刊
NATURE COMMUNICATIONS
卷 12, 期 1, 页码 -出版社
NATURE PORTFOLIO
DOI: 10.1038/s41467-020-20095-2
关键词
-
资金
- National Center for Research Resources
- National Center for Advancing Translational Sciences, National Institutes of Health [KL2 TR001416]
- Defense Advanced Research Projects Agency (DARPA) BTO [N66001-17-2-4023, N66001-18-2-4015]
- Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority [N6601-18-2-4015]
- Defense Threat Reduction Agency [HDTRA1-18-1-0036, HDTRA1-18-1-0035]
Diagnosis of COVID-19 by PCR testing may underestimate the true prevalence of infection; serologic methods are more accurate and versatile for monitoring disease burden and epidemiology. A protein microarray with antigens from SARS-CoV-2, SARS-CoV, MERS-CoV, and common human respiratory viruses has been reported as a diagnostic, epidemiologic, and research tool.
The current practice for diagnosis of COVID-19, based on SARS-CoV-2 PCR testing of pharyngeal or respiratory specimens in a symptomatic patient at high epidemiologic risk, likely underestimates the true prevalence of infection. Serologic methods can more accurately estimate the disease burden by detecting infections missed by the limited testing performed to date. Here, we describe the validation of a coronavirus antigen microarray containing immunologically significant antigens from SARS-CoV-2, in addition to SARS-CoV, MERS-CoV, common human coronavirus strains, and other common respiratory viruses. A comparison of antibody profiles detected on the array from control sera collected prior to the SARS-CoV-2 pandemic versus convalescent blood specimens from virologically confirmed COVID-19 cases demonstrates near complete discrimination of these two groups, with improved performance from use of antigen combinations that include both spike protein and nucleoprotein. This array can be used as a diagnostic tool, as an epidemiologic tool to more accurately estimate the disease burden of COVID-19, and as a research tool to correlate antibody responses with clinical outcomes. COVID-19 diagnosis is commonly performed by PCR testing, however, serologic methods are more accurate and versatile for monitoring disease burden and epidemiology. Here the authors report a protein microarray with antigens from SARS-CoV-2, SARS-CoV, MERS-CoV as well as common human respiratory viruses.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据